NCT07434063

Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Hebei Medical University Fourth Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, observational real-world study, aiming to observe and evaluate the efficacy and safety of prophylactic application of Mecapegfilgrastim Injection in tumor patients after radiotherapy/chemotherapy/immunotherapy in the real world to prevent neutropenia.The subjects who met the inclusion criteria of the protocol were defined as those who needed radiotherapy/chemotherapy/immunotherapy after being diagnosed with solid malignant tumors. The researchers believed that the subjects needed to use Mecapegfilgrastim Injection for primary/secondary prevention after receiving tumor treatment.

Conditions

• Neutropenia

Interventions

Type	Name	Description
DRUG	Mecapegfilgrastim Injection	Use it 24 hours after the end of each treatment cycle at a fixed dose of 6 mg or 100μg/kg each time

Timeline

• Start date: 2025-06-18
• Primary completion: 2026-12-31
• Completion: 2027-06-30
• First posted: 2026-02-25
• Last updated: 2026-02-25

Locations

1 site across 1 country: China